Conjunctivitis Clinical Trial
Official title:
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Grass (Phleum Pratense) Sublingual Tablet (SCH 697243) in Subjects Between 5 and 65 Years of Age, With a History of Grass Pollen-Induced Rhinoconjunctivitis, With or Without Asthma (Protocol No. P08067)
Verified date | September 2015 |
Source | Merck Sharp & Dohme Corp. |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
This is a study to evaluate the efficacy and safety of grass sublingual tablet (SCH 697243) versus placebo in the treatment of grass pollen-induced allergic hayfever symptoms. Participants will receive either the sublingual grass tablet or a placebo tablet during the study. It is expected that those participants receiving the active sublingual grass tablet will have less hayfever symptoms and need less medications to treat hayfever symptoms during the grass pollen season.
Status | Completed |
Enrollment | 1501 |
Est. completion date | August 2012 |
Est. primary completion date | August 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 5 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Must have a clinical history of significant allergic rhinoconjunctivitis to grass (with or without asthma) - Must have a positive skin prick test response to Phleum pratense (Timothy grass) - Must be positive for specific immunoglobulin E (IgE) against Phleum pratense (Timothy grass) - Must have an forced expiratory volume in 1 second (FEV1) of at least 70% of predicted value at Screening - Safety laboratory tests and vital signs conducted at the Screening Visit must be within normal limits or clinically acceptable to the investigator/sponsor Exclusion Criteria: - Has a clinical history of symptomatic seasonal allergic rhinitis and/or asthma due to another allergen during or potentially overlapping the GPS - Has a clinical history of significant symptomatic perennial allergic rhinitis and/or asthma due to an allergen to which the participant is regularly exposed - Has received an immunosuppressive treatment within 3 months prior to the Screening Visit - Has a clinical history of severe asthma - Has a history of anaphylaxis with cardiorespiratory symptoms - Has a history of self-injectable epinephrine use - Has a history of chronic urticaria and angioedema - Has a clinical history of chronic sinusitis during the 2 years prior to the Screening Visit - Has current severe atopic dermatitis - Is breast-feeding, pregnant, or intending to become pregnant - Had previous treatment by immunotherapy with any grass pollen allergen for more than 1 month within the 5 years prior to the Screening Visit - Ongoing treatment with any specific immunotherapy at the time of the Screening Visit - Has a known history of allergy, hypersensitivity or intolerance to the ingredients of the study drug (except for Phleum pratense), rescue medications, or self-injectable epinephrine - Has any clinically significant condition or situation, other than the condition being studied that, in the opinion of the investigator, would interfere with the study evaluations or optimal participation in the study. Specific examples include but are not limited to hypertension being treated with beta blockers, coronary artery disease, arrhythmia, stroke, ocular conditions requiring topical beta blockers, any condition requiring the use of beta blockers - Has used any investigational drugs within 30 days of the Screening Visit - Is participating in any other clinical study - Is a family member of the investigational study staff conducting this study - Is unable to meet medication washout requirements - Is unlikely to be able to complete the trial, for any reason, or likely to travel for extended periods of time during the GPS, which in the opinion of the investigator will compromise the data - Has a clinically significant abnormal vital sign or laboratory value that would preclude participation in the study |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Merck Sharp & Dohme Corp. |
Maloney J, Bernstein DI, Nelson H, Creticos P, Hébert J, Noonan M, Skoner D, Zhou Y, Kaur A, Nolte H. Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: a large randomized controlled trial. Ann Allergy Asthma Immunol. 2014 Feb;112(2):1 — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Average Total Combined Rhinoconjunctivitis Daily Symptom Score (DSS) and Rhinoconjunctivitis Daily Medication Score (DMS) Over the Entire Grass Pollen Season (GPS) | The total combined score was the sum of the rhinoconjunctivitis DSS and rhinoconjunctivitis DMS for the entire GPS (total score range: 0 to 54), with a lower score representing less rhinoconjunctivitis symptoms and use of medications. For rhinoconjunctivitis DSS, participants assessed a total of 6 rhinoconjunctivitis symptoms (runny nose, blocked nose, sneezing, itchy nose, gritty feeling/red/itchy eyes, and watery eyes) each on a scale of 0 to 3 (0=no symptoms, 1=mild symptoms, 2=moderate symptoms, 3=severe symptoms; score range: 0 to 18), with a lower score representing less rhinoconjunctivitis symptoms. For rhinoconjunctivitis DMS, participants reported their use of specific rescue medications with specific scores assigned to each medication (score range: 0 to 36), with a lower score representing less use of medications for rhinoconjunctivitis. |
Entire GPS (expected average duration of 5 to 6 weeks) | No |
Secondary | Average Rhinoconjunctivitis DSS Over the Entire GPS | For rhinoconjunctivitis DSS, participants assessed a total of 6 rhinoconjunctivitis symptoms (runny nose, blocked nose, sneezing, itchy nose, gritty feeling/red/itchy eyes, and watery eyes) each on a scale of 0 to 3 (0=no symptoms, 1=mild symptoms, 2=moderate symptoms, 3=severe symptoms; score range: 0 to 18), with a lower score representing less rhinoconjunctivitis symptoms. | Entire GPS (expected average duration of 5 to 6 weeks) | No |
Secondary | Average Total Combined Rhinoconjunctivitis DSS and Rhinoconjunctivitis DMS Over the Peak GPS | The total combined score was the sum of the rhinoconjunctivitis DSS and rhinoconjunctivitis DMS for the entire GPS (total score range: 0 to 54), with a lower score representing less rhinoconjunctivitis symptoms and use of medications. For rhinoconjunctivitis DSS, participants assessed a total of 6 rhinoconjunctivitis symptoms (runny nose, blocked nose, sneezing, itchy nose, gritty feeling/red/itchy eyes, and watery eyes) each on a scale of 0 to 3 (0=no symptoms, 1=mild symptoms, 2=moderate symptoms, 3=severe symptoms; score range: 0 to 18), with a lower score representing less rhinoconjunctivitis symptoms. For rhinoconjunctivitis DMS, participants reported their use of specific rescue medications with specific scores assigned to each medication (score range: 0 to 36), with a lower score representing less use of medications for rhinoconjunctivitis. |
Peak GPS (expected average duration of 2 weeks) | No |
Secondary | Average Rhinoconjunctivitis Quality of Life Questionnaire With Standardized Activities for Participants =12 Years of Age (RQLQ12+) Over the Peak GPS | The RQLQ12+ consists of 7 domains: Activities, Sleep, Non-Nose/Eye Symptoms, Practical Problems, Nasal Symptoms, Eye Symptoms, Emotional. Participants reflect on their experience over the previous 7 days and assess 28 items on a scale of 0 to 6 (0=Not troubled, 6=Extremely troubled; score range: 0-6 [mean of all domain scores]), with a higher score indicating more significant impairment due to seasonal allergic rhinoconjunctivitis. | Peak GPS (expected average duration of 2 weeks) | No |
Secondary | Average Rhinoconjunctivitis DMS Over the Entire GPS | For rhinoconjunctivitis DMS, participants reported their use of specific rescue medications with specific scores assigned to each medication (score range: 0 to 36), with a lower score representing less use of medications for rhinoconjunctivitis. | Entire GPS (expected average duration of 5 to 6 weeks) | No |
Secondary | Average Rhinoconjunctivitis DSS Over the Peak GPS | For rhinoconjunctivitis DSS, participants assessed a total of 6 rhinoconjunctivitis symptoms (runny nose, blocked nose, sneezing, itchy nose, gritty feeling/red/itchy eyes, and watery eyes) each on a scale of 0 to 3 (0=no symptoms, 1=mild symptoms, 2=moderate symptoms, 3=severe symptoms; score range: 0 to 18), with a lower score representing less rhinoconjunctivitis symptoms. | Peak GPS (expected average duration of 2 weeks) | No |
Secondary | Average Rhinoconjunctivitis DMS Over the Peak GPS | For rhinoconjunctivitis DMS, participants reported their use of specific rescue medications with specific scores assigned to each medication (score range: 0 to 36), with a lower score representing less use of medications for rhinoconjunctivitis. | Peak GPS (expected average duration of 2 weeks) | No |
Secondary | Average Paediatric Standardised Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ) Overall Score Over the Peak GPS (Participants 6 to <12 Years of Age) | For PRQLQ, participants assessed a total of 19 items within 5 domains: Nose Symptoms, Eye Symptoms, Practical Problems, Activity Limitation and Other Symptoms, each on a scale of 0 to 6 (0=Not troubled, 6=Extremely troubled; score range: 0 to 6 [mean of all domain scores]), with a higher score indicating more significant impairment due to seasonal allergic rhinoconjunctivitis. | Peak GPS (expected average duration of 2 weeks) | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00770315 -
Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05234)
|
Phase 3 | |
Completed |
NCT00783198 -
Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05233)(COMPLETED)
|
Phase 2/Phase 3 | |
Recruiting |
NCT06229379 -
The Effects of a Large Language Model on Clinical Questioning Skills
|
N/A | |
Not yet recruiting |
NCT03631108 -
Feasibility Study and Preliminary Application Study on Iris OCTA
|
||
Completed |
NCT01028027 -
Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis
|
Phase 3 | |
Completed |
NCT00978029 -
Safety Study of Ragweed Allergy Immunotherapy Tablet in Subjects 50 Years of Age and Older (Study P06081)
|
Phase 2 | |
Completed |
NCT00550550 -
Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED)
|
Phase 3 | |
Completed |
NCT00562159 -
Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED)
|
Phase 3 | |
Withdrawn |
NCT02795273 -
Efficacy and Safety of Grass-SPIRE Registration Study
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT01600365 -
Evaluate the Use of Ganciclovir Gel 0.3% for the Treatment of Conjunctivitis Caused by Adenovirus
|
Phase 3 | |
Completed |
NCT00567918 -
Phase III, Long-Term, Open-Label, Extension Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis
|
Phase 3 | |
Completed |
NCT04374656 -
Prevalence of SARS-CoV-2 in Conjunctival Swab Samples Among Patients With Conjunctivitis During the COVID-19 Pandemic
|
||
Completed |
NCT03753893 -
Ocular Manifestations in Rheumatic Diseases
|
||
Completed |
NCT02472223 -
Reducing Adenoviral Patient Infected Days
|
N/A | |
Completed |
NCT00001734 -
Screening for NEI Clinical Studies
|
N/A | |
Completed |
NCT00623701 -
Efficacy and Safety From a High-dosed Sublingual Grass Pollen Preparation
|
Phase 3 | |
Completed |
NCT00581542 -
Moxifloxacin vs. Polytrim for Conjunctivitis
|
Phase 4 | |
Completed |
NCT04287608 -
Observational Study of Conjunctivitis in the Setting of DUPIXENT® Treatment for Atopic Dermatitis
|
||
Completed |
NCT04984941 -
Evaluation of the Role of IgE Responses to Der p 1 and Der p 2 in Chinese House Dust Mite-Allergic Patients
|
||
Completed |
NCT00921895 -
A Comparison of the RPS Adeno Detector IV to Viral Cell Culture at Detecting Adenoviral Conjunctivitis
|
N/A |